FOXO announces transformational transaction to list on NYSE
FOXO announces transformational transaction to list on NYSE
FOXO announces transformational transaction to list on NYSE
FOXO announces transformational transaction to list on NYSE
FOXO announces transformational transaction to list on NYSE.
CEO Jon Sabes to discuss transaction on Feb 25, 2022 at 10AM ET
A unique investment opportunity
Investor Deck
Download now
Feb 24, 2022
GLOBAL NEWSWIRE Feb 24, 2022
FOXO Technologies Inc. expected to become publicly listed via business combination with Delwinds Insurance Acquisition Corp and plans to trade on the NYSE under ticker symbol 'FOXO'.
GenomeWeb July 25, 2021
Epigenetic Biomarker Firm Foxo Technologies Raises $10M
Society of Actuaries 2020
Epigenetics: A White Paper on Technology and Innovation Applying Modern Biotechnology to Life Insurance Underwriting
Press Releases
Keep track of our latest news and insights
YAHOO Apr 8, 2021
FOXO Technologies Inc. Announces Closing of $10 Million Investment to Launch FOXO Life and Continue Commercializing Epigenetic Biomarker Technology
Star Tribune Apr 08, 2021
Minnesota firms pull in $500M of venture capital in first half of year
Coverager April 8, 2021
FOXO Technologies raises $10 million